Secondary Prevention of Stroke: The role of the General Practitioner
Poster Apr 23, 2013
The increased risk of ischaemic events following a stroke, and the associated morbidity and mortality, makes secondary prevention an important therapeutic goal. Nevertheless, for reasons relating to both physicians and patients, a well documented gap remains between evidence and clinical practice in many aspects of cardiovascular disease.
Reducing the burden of recurrent stroke clearly relies not only on an increasing understanding of the aetiologial factors that influence the development of stroke, but also on the services of primary care physicians such as lifestyle modifications, pharmacological treatment and referral for consideration of surgery.
Assessment of secondary prevention and the discrepancy between evidence and practice is difficult due to the variations between clinical studies, for example in different target populations, length of follow up, drop out rates and outcomes. It is similarly challenging to relate the results of these clinical trials to individual patients, each with numerous risk factors of varying significance.
Bioluminescent Kinase Profiling Systems For Characterizing Small Molecule Kinase InhibitorsPoster
In order to profile compounds against a broad panel of kinases, in-house profiling requires rigorous kinase assay development.READ MORE
Assessment of Oral LISPRO Treatment in Ameliorating Amyloid and Tau Pathology in Transgenic Alzheimer’s Mice ModelPoster
Ionic co-crystals of lithium salicylate with organic proline (LISPRO) showed better safety and pharmacokinetic profile of lithium in plasma and brain of wild-type and transgenic Alzheimer mice model compared to lithium salts.READ MORE
CiPA Phase 2 Study: validation of an automated microelectrode array (MEA) assay of hiPSC-derived cardiomyocyte electrophysiology for cardiac safety evaluationPoster
These results support the use of hSC-CM and MEA technology for preclinical assessment of proarrhythmic risk within the proposed CiPA paradigm, and, more generally, demonstrate that automation of the CM-MEA assay can achieve high reliability and throughput for cardiac risk assessment in vitro.READ MORE